Citations

Showing 10 of 108152 citations.

Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug‐Resistant Pseudomonas aeruginosa : A Case Report
Stevens, Ryan W. , Clancy, Megan, Stevens, Ryan W

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 24, 2019 | Volume: 39 | Issue: 11 | Pages: 1113-1118

10.1002/phar.2334 | PMID 31550054 Get It

Multidrug‐resistant (MDR) Pseudomonas aeruginosa infections often represent a therapeutic challenge requiring utilization of older, more toxic antibiotics, or new agents with limited data. Once susceptibility to β‐lactam and fluoroquinolone antibiotics has been lost, other therapeutic options such as aminoglycoside or polymyxin antibiotics carry significant adverse effects such as nephrotoxicity, neurotoxicity, and ototoxicity. A novel cephalosporin, cefiderocol, lacks gram‐positive and anaerobic activity but offers broad coverage of gram‐negative bacteria, including P. aeruginosa . A unique catechol side chain gives it activity as a siderophore, thereby increasing bacterial uptake and decreasing efflux. Additionally, cefiderocol is stable against a wide array of β‐lactamases. Despite these promising characteristics, there are minimal data currently available in the literature detailing the use of cefiderocol in the treatment of MDR P. aeruginosa infections. We present a case of a 46‐year‐old man who developed an MDR P. aeruginosa intraabdominal infection where serious and life‐threatening toxicities to aminoglycosides and polymyxin antibiotics led to the utilization of cefiderocol on compassionate use approval. The isolate was susceptible to cefiderocol, and the patient was treated for 28 days of therapy. He demonstrated clinical and radiographic resolution of his infection and was discharged to home.
Response to Luthra et al.
Hu, Yiqun , Datto, Catherine , Creanga, Dana, Camilleri, Michael , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | September 24, 2019 | Volume: 114 | Issue: 10 | Pages: 1695-1695

10.14309/ajg.0000000000000402 | PMID 31567191 Get It

One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis
Ackerman, Steven J. , Kagalwalla, Amir F. , Hirano, Ikuo , Gonsalves, Nirmala , Katcher, Paul Menard, Gupta, Sandeep K. , Grozdanović, Milica, Pan, Zhaoxing , Masterson, Joanne C. , Fantus, Robert J., Alumkal, Preeth, Ochkur, Sergei I. , Ahmed, Faria , Melín‐Aldana, Héctor, Biette, Kathryn A. , Dubner, Allison , Amsden, Katie, Keeley, Kaitlin, Sulkowski, Maureen, Zalewski, Angelika , Atkins, Dan, Furuta, Glenn T. , Ochkur, Sergei, Wechsler, Joshua B , Du, Jian, Lee, James J. , Capocelli, Kelley E.

Mayo Clinic

American Journal of Gastroenterology | September 24, 2019 | Volume: 114 | Issue: 10 | Pages: 1614-1625

10.14309/ajg.0000000000000371 | PMID 31567192 Get It

OBJECTIVES: Eosinophilic esophagitis (EoE), a chronic food allergic disease, lacks sensitive and specific peripheral biomarkers. We hypothesized that levels of EoE-related biomarkers captured using a 1-hour minimally invasive Esophageal String Test (EST) would correlate with mucosal eosinophil counts and tissue concentrations of these same biomarkers. We aimed to determine whether a 1-hour EST accurately distinguishes active from inactive EoE or a normal esophagus. METHODS: In a prospective, multisite study, children and adults (ages 7–55 years) undergoing a clinically indicated esophagogastroduodenoscopy performed an EST with an esophageal dwell time of 1 hour. Subjects were divided into 3 groups: active EoE, inactive EoE, and normal esophageal mucosa. Eosinophil-associated protein levels were compared between EST effluents and esophageal biopsy extracts. Statistical modeling was performed to select biomarkers that best correlated with and predicted eosinophilic inflammation. RESULTS: One hundred thirty-four subjects (74 children, 60 adults) with active EoE (n = 62), inactive EoE (n = 37), and patient controls with a normal esophagus (n = 35) completed the study. EST-captured eosinophil-associated biomarkers correlated significantly with peak eosinophils/high-power field, endoscopic visual scoring, and the same proteins extracted from mucosal biopsies. Statistical modeling, using combined eotaxin-3 and major basic protein-1 concentrations, led to the development of EoE scores that distinguished subjects with active EoE from inactive EoE or normal esophagi. Eighty-seven percent of children, 95% of parents, and 92% of adults preferred the EST over endoscopy if it provided similar information. DISCUSSION: The 1-hour EST accurately distinguishes active from inactive EoE in children and adults and may facilitate monitoring of disease activity in a safe and minimally invasive fashion.
Helicobacter pylori infection in Indigenous Australians: a serious health issue?
Talley, Nicholas J.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 182 | Issue: 5 | Pages: 205-206

10.5694/j.1326-5377.2005.tb06666.x | PMID 15748127 Get It

Non‐ulcer dyspepsia: a readily‐treatable disorder with no relation to Campylobacter pylori
Talley, Nicholas J.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 148 | Issue: 2 | Pages: 104-104

10.5694/j.1326-5377.1988.tb104535.x Get It

Non‐ulcer dyspepsia: a readily‐treatable disorder with no relation to Campylobacter pylori
Graham, John R., Talley, Nicholas J. , Graham, John R.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 148 | Issue: 2 | Pages: 104-104

10.5694/j.1326-5377.1988.tb104534.x Get It

Risks of proton‐pump inhibitors: what every doctor should know
Talley, Nicholas J.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 190 | Issue: 3 | Pages: 109-110

10.5694/j.1326-5377.2009.tb02305.x | PMID 19203303 Get It

Economic impact of contact force sensing in catheter ablation for atrial fibrillation
Mansour, Moussa , Reddy, Vivek Y. , Karst, Edward , Heist, E. Kevin , Packer, Douglas L. , Dalal, Nirav, Agarwal, Rahul , Calkins, Hugh , Ruskin, Jeremy N. , Mahapatra, Srijoy, Heist, Edwin Kevin , Reddy, Vivek Y

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 24, 2019 | Volume: 30 | Issue: 11 | Pages: 2302-2309

10.1111/jce.14189 | PMID 31549456 Get It

AbstractAimsThe TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) clinical trial compared clinical outcomes using a contact force (CF) sensing ablation catheter (TactiCath) with a catheter that lacked CF measurement. This analysis links recorded events in the TOCCASTAR study and a large claims database, IBM MarketScan®, to determine the economic impact of using CF sensing during atrial fibrillation (AF) ablation.Methods and ResultsClinical events including repeat ablation, use of antiarrhythmic drugs, hospitalization, perforation, pericarditis, pneumothorax, pulmonary edema, pulmonary vein stenosis, tamponade, and vascular access complications were adjudicated in the year after ablation. CF was characterized as optimal if greater than or equal to 90% lesion was performed with greater than or equal to 10 g of CF. A probabilistic 1:1 linkage was created for subjects in MarketScan® with the same events in the year after ablation, and the cost was evaluated over 10 000 iterations. Of the 279 subjects in TOCCASTAR, 145 were ablated using CF (57% with optimal CF), and 134 were ablated without CF. In the MarketScan® cohort, 9811 subjects who underwent AF ablation were used to determine events and costs. For subjects ablated with optimal CF, total cost was $19 271 ± 3705 in the year after ablation. For ablation lacking CF measurement, cost was $22 673 ± 3079 (difference of $3402, P < .001). In 73% of simulations, optimal CF was associated with lower cost in the year after ablation.ConclusionCompared to ablation without CF, there was a decrease in healthcare cost of $3402 per subject in the first year after the procedure when optimal CF was used.
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
Jung, Deok‐Beom , Yun, Miyong , Kim, Eun-Ok , Kim, Bonglee , Wang, Enfeng , Hammond, Edward , Dredge, Keith , Shridhar, Viji , Kim, Jaekwang , Jung, Ji Hoon , Mukhopadhyay, Debabrata , Hammond, Edward, Kim, Sung‐Hoon

Mayo Clinic

Oncotarget | September 24, 2019 | Volume: 10 | Issue: 54 | Pages: 5669-5669

10.18632/oncotarget.27216 | PMID 31608142 Get It